Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases
{{output}}
Background: Patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations frequently develop brain metastases (BM). While KRAS G12C was once considered an undruggable target, the emergence of selective inhibitors... ...
